If a patient misses a dose of Kisqali (ribociclib), should they take the missed dose or continue the regular dosing schedule?

Missed Dose of Kisqali: Do Not Double Up—Continue Regular Schedule

If a patient misses a dose of Kisqali (ribociclib) or vomits after taking a dose, they should NOT take another dose that day and should simply take their next scheduled dose at the regular time. 1

Clear FDA Guidance

The FDA-approved prescribing information for Kisqali provides explicit instructions for missed doses:

• Do not take another dose on the same day if a dose is missed or vomited
• Resume with the next scheduled dose at the regular time
• Do not attempt to "make up" the missed dose 1

This recommendation applies to Kisqali's once-daily dosing regimen (3 weeks on, 1 week off schedule).

Rationale Behind This Approach

Kisqali has a relatively short half-life (approximately 30-55 hours), which means drug levels decline predictably between doses. The "wait-and-see" strategy used for medications with short half-lives is appropriate here—simply continuing the regular schedule maintains therapeutic drug levels without risking overdose or increased toxicity 2.

Taking a double dose would significantly increase exposure and could precipitate serious adverse events, particularly:

• QT prolongation (already a concern at standard doses, occurring in 5.2% of patients) 3
• Severe neutropenia (grade 3-4 neutropenia occurs in 43.8% of patients) 3
• Hepatotoxicity (liver-related adverse events lead to discontinuation in 8.9% of patients) 3

Critical Safety Considerations

The risk of doubling up outweighs any theoretical benefit from "catching up":

• Ribociclib already requires frequent dose reductions (57% of patients in real-world studies needed reduction to 400 mg, and 23% to 200 mg) 4
• Only 20% of older patients continued the full 600-mg dose without modification 4
• Grade 3-4 adverse events occur in 67% of patients at standard dosing 4

Missing a single dose in the context of continuous therapy (years of treatment in early breast cancer, ongoing treatment in metastatic disease) has minimal impact on overall efficacy, whereas doubling doses increases immediate toxicity risk substantially.

Common Pitfall to Avoid

Do not apply general principles about "making up" missed doses from other medications to Kisqali. While some medications with long half-lives and high thrombotic risk (like certain anticoagulants) may warrant taking a makeup dose under specific circumstances 2, Kisqali's toxicity profile and the nature of cancer treatment make this approach inappropriate.

Patient Counseling Points

Patients should be educated that:

• Missing one dose will not compromise their cancer treatment
• Taking extra medication increases serious side effect risk
• They should contact their healthcare provider if they frequently miss doses, as this may indicate need for adherence support
• They should never take damaged, broken, or cracked tablets 1

The priority is maintaining safety while preserving long-term adherence—doubling doses after missed doses would increase toxicity and potentially lead to treatment discontinuation, which would be far more detrimental to outcomes than missing an occasional single dose.